http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102207319-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_942782ef91e65ecc67141721d44d38eb
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
filingDate 2020-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ef91413d3cecc75ea8e538eec6d1e27
publicationDate 2021-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-102207319-B1
titleOfInvention New Empagliflozin cocrystal
abstract As a result of trying to improve the low stability and water solubility, which are the problems of empagliflozin, we developed an empagliflozin co-crystal with increased stability and water solubility more than 120 times. The empagliflozin co-crystal according to the present invention is a new solid form in which the stability and water solubility of the known empagliflozin crystalline form is overcome, and is very useful as an optimal raw material drug substance capable of maximizing utilization as a drug.
priorityDate 2020-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006117359-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018362514-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017203457-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011039107-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005092877-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7405
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25552
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID282361
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537902
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID6524
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID6523
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID246787
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID64522
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421421992
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6322
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6573
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID20537
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID399680
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414859288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419548926
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11949646

Total number of triples: 40.